In particular, the combination of immunotherapeutic strategies with peptide inhibitors of TGF-β was able to enhance the efficacy of immunotherapy, suggesting that these compounds may be useful for future clinical application in cancer immunotherapy [41]. Here, TGFB1 is linked to cancer.